Schedule 13G ownership disclosure

ALNYLAM PHARMACEUTICALS INC COM

Security class unavailable · CUSIP: 02043Q107

Event date: 2024-09-30

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
5,018,779
Percent of class
3.9100%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000902219-24-000383
Form type
SC 13G/A
Filer
ALNYLAM PHARMACEUTICALS, INC.
CIK
CIK 1178670
Filed
Nov 08, 2024
Reporting period
Sep 30, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub